Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection.
SARS-CoV-2
autoantibodies
autoimmunity
infection
rheumatoid arthritis
rheumatoid factor
vaccination
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
13
10
2023
accepted:
15
02
2024
medline:
18
3
2024
pubmed:
15
3
2024
entrez:
15
3
2024
Statut:
epublish
Résumé
Rheumatoid factors (RFs) are autoantibodies that target the Fc region of IgG, and are found in patients with rheumatic diseases as well as in the healthy population. Many studies suggest that an immune trigger may (transiently) elicit RF responses. However, discrepancies between different studies make it difficult to determine if and to which degree RF reactivity can be triggered by vaccination or infection. We quantitatively explored longitudinal RF responses after SARS-CoV-2 vaccination and infection in a well-defined, large cohort using a dual ELISA method that differentiates between true RF reactivity and background IgM reactivity. In addition, we reviewed existing literature on RF responses after vaccination and infection. 151 healthy participants and 30 RA patients were included to measure IgM-RF reactivity before and after SARS-CoV-2 vaccinations by ELISA. Additionally, IgM-RF responses after a SARS-CoV-2 breakthrough infection were studied in 51 healthy participants. Published prevalence studies in subjects after infection report up to 85% IgM-RF seropositivity. However, seroconversion studies (both infection and vaccination) report much lower incidences of 2-33%, with a trend of lower percentages observed in larger studies. In the current study, SARS-CoV-2 vaccination triggered low-level IgM-RF responses in 5.5% (8/151) of cases, of which 1.5% (2/151) with a level above 10 AU/mL. Breakthrough infection was accompanied by development of an IgM-RF response in 2% (1/51) of cases. Our study indicates that
Sections du résumé
Background
UNASSIGNED
Rheumatoid factors (RFs) are autoantibodies that target the Fc region of IgG, and are found in patients with rheumatic diseases as well as in the healthy population. Many studies suggest that an immune trigger may (transiently) elicit RF responses. However, discrepancies between different studies make it difficult to determine if and to which degree RF reactivity can be triggered by vaccination or infection.
Objective
UNASSIGNED
We quantitatively explored longitudinal RF responses after SARS-CoV-2 vaccination and infection in a well-defined, large cohort using a dual ELISA method that differentiates between true RF reactivity and background IgM reactivity. In addition, we reviewed existing literature on RF responses after vaccination and infection.
Methods
UNASSIGNED
151 healthy participants and 30 RA patients were included to measure IgM-RF reactivity before and after SARS-CoV-2 vaccinations by ELISA. Additionally, IgM-RF responses after a SARS-CoV-2 breakthrough infection were studied in 51 healthy participants.
Results
UNASSIGNED
Published prevalence studies in subjects after infection report up to 85% IgM-RF seropositivity. However, seroconversion studies (both infection and vaccination) report much lower incidences of 2-33%, with a trend of lower percentages observed in larger studies. In the current study, SARS-CoV-2 vaccination triggered low-level IgM-RF responses in 5.5% (8/151) of cases, of which 1.5% (2/151) with a level above 10 AU/mL. Breakthrough infection was accompanied by development of an IgM-RF response in 2% (1/51) of cases.
Conclusion
UNASSIGNED
Our study indicates that
Identifiants
pubmed: 38487524
doi: 10.3389/fimmu.2024.1314507
pmc: PMC10937420
doi:
Substances chimiques
Rheumatoid Factor
9009-79-4
COVID-19 Vaccines
0
Autoantibodies
0
Immunoglobulin M
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1314507Informations de copyright
Copyright © 2024 Keijzer, Oskam, Ooijevaar-de Heer, Steenhuis, Keijser, Wieske, van Dam, Stalman, Kummer, Boekel, Kuijpers, ten Brinke, van Ham, Eftimov, Tas, Wolbink and Rispens.
Déclaration de conflit d'intérêts
TR and GW are inventors on a patent application based on the use of bioengineered IgG targets for the characterization of rheumatoid factor reactivity patterns. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Exp Immunol. 1978 Jan;31(1):100-3
pubmed: 639341
Ann Rheum Dis. 1987 Sep;46(9):674-80
pubmed: 3499874
Ann Rheum Dis. 2021 Aug;80(8):1096-1098
pubmed: 33648960
Acta Pathol Microbiol Scand. 1962;56:478-9
pubmed: 14011370
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1517-20
pubmed: 22034113
Front Immunol. 2023 Jan 25;13:1059714
pubmed: 36761174
Eur Cytokine Netw. 2021 Dec 1;32(4):83-88
pubmed: 35118946
Clin Exp Immunol. 1991 Oct;86(1):43-8
pubmed: 1914235
Ann Rheum Dis. 2006 Aug;65(8):1110-2
pubmed: 16361276
J Infect Dis. 2022 Jun 15;225(12):2155-2162
pubmed: 35079804
Semin Arthritis Rheum. 2019 Feb;48(4):603-610
pubmed: 30032973
Clin Exp Immunol. 1982 Feb;47(2):275-82
pubmed: 7075025
Clin Vaccine Immunol. 2006 Feb;13(2):301
pubmed: 16467342
Isr Med Assoc J. 2019 Jul;21(7):480-486
pubmed: 31507125
J Clin Microbiol. 1985 Jul;22(1):89-94
pubmed: 3894413
Clin Immunol. 2002 Jul;104(1):1-13
pubmed: 12139942
Lancet Rheumatol. 2022 May;4(5):e338-e350
pubmed: 35317410
Br J Rheumatol. 1993 Jul;32(7):546-9
pubmed: 8339123
Arthritis Rheum. 1965 Aug;8:524-9
pubmed: 14323541
J Inflamm Res. 2021 Jul 12;14:3123-3128
pubmed: 34285538
Front Med (Lausanne). 2023 Jul 07;10:1201425
pubmed: 37484859
J Transl Autoimmun. 2021;4:100091
pubmed: 33681751
Clin Exp Immunol. 1987 Feb;67(2):236-44
pubmed: 3608224
Mult Scler. 2023 Mar;29(3):457-460
pubmed: 36448735
Ann Rheum Dis. 2006 Feb;65(2):191-4
pubmed: 16014674
Cell Rep Med. 2022 Jun 21;3(6):100663
pubmed: 35732153
Ann Rheum Dis. 2023 Jul;82(7):945-956
pubmed: 37055152
Arthritis Rheumatol. 2020 Dec;72(12):2005-2016
pubmed: 32648642
Arthritis Rheum. 1976 Sep-Oct;19(5):887-90
pubmed: 962970
Vaccine. 1993;11(5):582-6
pubmed: 8488716
Clin Exp Immunol. 1985 Aug;61(2):379-87
pubmed: 2412746
Eur J Immunol. 1978 Apr;8(4):279-85
pubmed: 668802
Clin Exp Immunol. 1983 Feb;51(2):299-304
pubmed: 6601551
Clin Exp Immunol. 1986 Dec;66(3):648-53
pubmed: 3568452
Eur J Immunol. 1996 Oct;26(10):2480-6
pubmed: 8898963
J Autoimmun. 2021 Aug;122:102682
pubmed: 34214763
J Clin Immunol. 1988 Sep;8(5):390-6
pubmed: 3182966
Am J Med. 2015 Sep;128(9):950-5
pubmed: 25837517
Clin Immunol Immunopathol. 1993 Apr;67(1):50-4
pubmed: 8443984
Clin Chem Lab Med. 2018 Sep 25;56(10):1749-1758
pubmed: 29427550
Ann Rheum Dis. 2022 Dec;81(12):1757-1766
pubmed: 36357161
Proc Soc Exp Biol Med. 1967 Jan;124(1):229-33
pubmed: 6017774
Diagnostics (Basel). 2023 May 25;13(11):
pubmed: 37296705
Ann Rheum Dis. 1969 Mar;28(2):104-20
pubmed: 4180579
Vaccines (Basel). 2023 Feb 17;11(2):
pubmed: 36851352